Sunesis Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 80   

Articles published

SNSS 2.36 +0.02 (0.85%)
price chart
Update: Sunesis Pharmaceuticals, Inc. Short Interest Disclosure
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has witnessed a colossal drop of 9.7% or 561,782 shares in its short figure.
Mid-Day Changers: Immune Pharmaceuticals, Inc. (IMNP), Sunesis ...  WallStreet Scope
BTIG Research Rating Disclosure on Sunesis Pharmaceuticals, Inc.  Winston View
BTIG Initiates Coverage On Sunesis Pharmaceuticals, Believes Company 'Will ...
BTIG initiated coverage on Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) Monday with a Buy rating and $5.50 price target.
Sunesis Pharmaceuticals Coverage Initiated by Analysts at BTIG Research (SNSS)  WKRB News
BTIG Research Begins Coverage on Sunesis Pharmaceuticals (SNSS)  Mideast Time
Related articles »  
Is This the Sunesis Resurrection?
In early October, Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) announced that its Phase 3 clinical trial of vosaroxin and cytarabine failed to meet the primary endpoint of the study, which ultimately had catastrophic results for the stock price ...
Sunesis Pharmaceuticals (SNSS) Stock Surges on Upcoming Announcement of ...  TheStreet.com
Related articles »  
Sunesis Pharmaceuticals, Inc. (SNSS) Jumps: Stock Rises 9%
Sunesis Pharmaceuticals, Inc. (SNSS - Snapshot Report) was a big mover last session, as the company saw its shares rise more than 9% on the day.
Related articles »  
Ahead of the Bell: Sunesis Pharma shares sink
Sunesis said it will seek marketing approval from European regulators and also will meet with the U.S. Food and Drug Administration to determine the "appropriate regulatory path forward.
Qinprezo Phase 3 trial fails (SNSS)  Seeking Alpha (registration)
Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin ...  MarketWatch
Related articles »  
Sunesis Pharmaceuticals Inc Stock Downgraded (SNSS)
This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, SUNESIS PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and ...
Related articles »  
BTIG Starts Sunesis Pharmaceuticals Inc. (SNSS) at Buy
Analyst Hartaj Singh said, "We believe current valuation reflects the Street assuming a 15-20% probability of vosaroxin approval in the US and EU.
UPDATE: UBS Starts Sunesis Pharmaceuticals Inc. (SNSS) at Buy
UBS initiated coverage on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) with a Buy rating and a price target of $14.00. Analyst Andrew Peters said, "Key points from our analysis: [1] SNSS provides an exceptionally high risk/reward ahead of the ph3 VALOR ...
Related articles »  
Short Interest of Sunesis Pharmaceuticals, Inc. Drops by 10%
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) reported a drop of 10% or 639,351 shares in its short interest. The short figure came in at 12.2% of the total floats.
Trader's Round Up:Millennial Media, Inc.(MM),Sunesis Pharmaceuticals ...  Investor Wired (press release)
Sunesis Pharmaceuticals Given Average Rating of "Hold" by Analysts ...  WKRB News
UPDATE: Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals (SNSS) to Buy ...
Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) gained Wednesday after being upgraded to Buy from Hold with a price target of $4 (from $2) by analyst Mara Goldstein of Cantor Fitzgerald.
Sunesis Pharmaceuticals Given Average Recommendation of �Hold� by ...  sleekmoney
Sunesis Pharmaceuticals Raised to Buy at Cantor Fitzgerald (SNSS)  Ticker Report
Related articles »